Whooping cough vaccine safety under the microscope in thailand

NCT ID NCT07400120

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at the safety of the VacPertagen whooping cough vaccine in over 5,400 people in Thailand, including pregnant women and their newborns. Healthcare workers reported any side effects after vaccination using standard forms. The goal was to catch any unexpected safety issues in a real-world setting beyond the initial trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VacPertagen (recombinant acellular pertussis vaccine)
What this could lead to
If the results confirm a good safety profile, this could support continued use of VacPertagen to protect against whooping cough in a broader population.
What could go wrong
This is an observational safety study, not a test of how well the vaccine works. It cannot prove effectiveness, and rare side effects may still be missed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERTUSSIS (WHOOPING COUGH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • BioNet-Asia Co.,Ltd.

    Bangkok, Bangkok, 10260, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.